Warsh Nomination: Market Pricing Zero Cuts vs. Broker Forecasts

Money markets have repriced Fed policy expectations sharply lower. Traders now price zero Fed rate cuts for 2026, a decisive reversal from the two cuts priced before the Middle East conflict escalated. This shift, tracked by the CME Group's FedWatch Tool, shows the market's immediate dovish bet on a prolonged pause.

The Fed's own latest statement, issued in March, maintained rates at 3-1/2 to 3-3/4 percent and cited "uncertainty about the economic outlook" and "inflation remains somewhat elevated." This cautious stance, driven by renewed inflation concerns from the conflict, directly contradicts the market's new baseline.

The Divergence: Market Pricing vs. Broker Forecasts

The market's zero-cut baseline now stands in stark contrast to the institutional forecast. Major brokerages like Goldman Sachs and Barclays still forecast two U.S. Federal Reserve interest-rate cuts in 2026, a view that persists even as money markets have repriced to no easing. This gap between the market's pricing and analyst expectations is a clear source of potential instability.

That divergence creates a liquidity risk. The market is pricing in a prolonged pause, while the consensus view among major banks points to a dovish path. This setup can lead to volatility if the Fed's actual policy or communication fails to align with either side. The uncertainty itself acts as a friction, dampening the flow of capital into risk assets.

The next institutional test arrives on April 16, when the Senate Banking Committee holds a hearing on President Trump's nominee, Kevin Warsh. The outcome of that process, and the broader debate over Fed independence, will be a key variable that could quickly resolve or exacerbate the current disconnect.

Catalysts and Risks: The Probe and the Hearing

The dovish market narrative faces two binary events that could quickly unravel it. The first is a separate criminal probe into the Federal Reserve's building expenses, which is now a direct roadblock. Senator Thom Tillis has stated he won't vote for Warsh until the probe is resolved, creating a clear condition for his support. The probe's status is critical because it could derail the nomination despite the market's zero-cut pricing.

The second event is the April 16 Senate Banking Committee hearing, which is moving ahead. A smooth confirmation process at this hearing would likely solidify the market's dovish shift. However, the setup is inherently conflicted. President Trump's goals are now in direct opposition: he cannot both confirm Warsh and allow the probe to move forward. By scheduling the hearing, he is attempting to push confirmation while the probe's legal status remains in limbo.

The risk is that the probe's unresolved nature creates a political overhang. Even if the hearing proceeds, Tillis's opposition means the nomination could stall in the full Senate. This uncertainty acts as a friction, potentially dampening the flow of capital that the market's dovish bet depends on. The outcome hinges on whether the probe is dropped or resolved before the confirmation vote.